<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01687998</url>
  </required_header>
  <id_info>
    <org_study_id>11949</org_study_id>
    <secondary_id>I1V-MC-EIAN</secondary_id>
    <nct_id>NCT01687998</nct_id>
  </id_info>
  <brief_title>A Study of Evacetrapib in High-Risk Vascular Disease</brief_title>
  <acronym>ACCELERATE</acronym>
  <official_title>Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the ACCELERATE study is to evaluate the efficacy and safety of evacetrapib in&#xD;
      participants with high-risk vascular disease (HRVD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study termination due to insufficient efficacy.&#xD;
  </why_stopped>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Composite Primary Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, Coronary Revascularization, or Hospitalization for Unstable Angina (UA)</measure>
    <time_frame>Baseline to Study Completion (Up to 4 years)</time_frame>
    <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline to 3 Months in Low-Density (LDL-C) and High-Density Lipoprotein Cholesterol (HDL-C) Levels</measure>
    <time_frame>Baseline, 3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite Endpoint of All-Cause Mortality, MI, Stroke, Coronary Revascularization, or Hospitalization for UA</measure>
    <time_frame>Baseline through End of Study (Up to 4 years)</time_frame>
    <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite Endpoint of CV Death, MI, or Coronary Revascularization</measure>
    <time_frame>Baseline through End of Study (Up to 4 years)</time_frame>
    <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite Endpoint of CV Death, MI, Stroke, or Hospitalization for UA</measure>
    <time_frame>Baseline through End of Study (Up to 4 years)</time_frame>
    <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Triple Composite Endpoint of CV Death, MI, or Stroke</measure>
    <time_frame>Baseline through End of Study (Up to 4 years)</time_frame>
    <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12092</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Evacetrapib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants will also receive standard of care for high-risk vascular disease (HRVD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, tablet administered orally once daily for up to 4 years. Participants will also receive standard of care for HRVD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evacetrapib</intervention_name>
    <description>Administered Orally</description>
    <arm_group_label>Evacetrapib</arm_group_label>
    <other_name>LY2484595</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered Orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of high risk vascular disease (HRVD) (that is, meet at least one of the&#xD;
             disease diagnostic criteria of: 1)History of acute coronary syndrome (ACS) (that is,&#xD;
             ≥30 days through 365 days after discharge for ACS) 2)cerebrovascular atherosclerotic&#xD;
             disease 3)peripheral arterial disease 4)diabetes mellitus with documented coronary&#xD;
             artery disease and are clinically stable (as judged by the responsible physician).&#xD;
&#xD;
          -  Must be treated with a statin for at least 30 days prior to screening. If not treated&#xD;
             with a statin must have documented statin intolerance, or contraindication to statin&#xD;
&#xD;
          -  Have a screening high-density lipoprotein cholesterol (HDL-C) ≤80 milligram per&#xD;
             deciliter (mg/dL) (≤2.1 millimole per liter [mmol/L])&#xD;
&#xD;
          -  Have screening triglycerides (TG) ≤400 mg/dL (≤4.5 mmol/L)&#xD;
&#xD;
          -  Meet 1 of the following criteria:&#xD;
&#xD;
               -  screening low-density lipoprotein cholesterol (LDL-C) no more than 10 mg/dL (0.3&#xD;
                  mmol/L) above the target chosen by the investigator (either LDL-C &lt;100 mg/dL&#xD;
                  [&lt;2.6 mmol/L] or LDL-C &lt;70 mg/dL [&lt;1.8 mmol/L]), OR&#xD;
&#xD;
               -  if LDL-C is greater than target, the participant must be on maximum tolerated&#xD;
                  statin dose (for at least 30 days), have documented statin intolerance, or&#xD;
                  contraindication to statin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are currently enrolled in, or discontinued within the last 30 days from, a clinical&#xD;
             trial involving an investigational product or non-approved use of a drug or device, or&#xD;
             concurrently enrolled in any other type of medical research judged not to be&#xD;
             scientifically or medically compatible with this study&#xD;
&#xD;
          -  Have previously completed or withdrawn from this study, or withdrawn from any other&#xD;
             study investigating evacetrapib&#xD;
&#xD;
          -  Female participants who are known to be pregnant or breastfeeding&#xD;
&#xD;
          -  Women of child-bearing potential only, who test positive for pregnancy between&#xD;
             screening and randomization, or who do not agree to use a reliable method of birth&#xD;
             control during the study&#xD;
&#xD;
          -  History of transient ischemic attack (TIA) or ischemic stroke &lt;30 days and ACS &lt;30&#xD;
             days&#xD;
&#xD;
          -  Any reading of systolic blood pressure ≥180 millimeter of mercury (mm Hg) or diastolic&#xD;
             blood pressure ≥110 mm Hg at screening or randomization&#xD;
&#xD;
          -  History of hemorrhagic stroke or intracranial hemorrhage&#xD;
&#xD;
          -  New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
          -  Serum creatinine &gt;2.2 mg/dL (&gt;194.5 micromole per liter [μmol/L]) at screening&#xD;
&#xD;
          -  Clinically active liver disease. Participants are not excluded due to Gilbert's&#xD;
             Syndrome or a history of cholelithiasis/cholecystectomy&#xD;
&#xD;
          -  History of malignancy within the preceding 3 years prior to screening&#xD;
&#xD;
          -  Known malabsorption syndrome with the exception of lactose intolerance&#xD;
&#xD;
          -  Participants with a known history of primary or secondary hyperaldosteronism&#xD;
&#xD;
          -  Participants with a history of intolerance/hypersensitivity to cholesterol ester&#xD;
             transfer protein (CETP) inhibitors&#xD;
&#xD;
          -  Any clinically significant medical condition that according to the investigator could&#xD;
             interfere with participation in the study&#xD;
&#xD;
          -  Participants whose life expectancy is anticipated to be less than 4 years&#xD;
&#xD;
          -  Unable or unwilling to comply with study requirements, or deemed by the investigator&#xD;
             to be unfit for the study&#xD;
&#xD;
          -  Have a history of drug, alcohol, or substance abuse within the past 6 months, as&#xD;
             assessed by the investigator&#xD;
&#xD;
          -  Concurrent or anticipated need for treatment with niacin &gt;250 mg/day or for chronic&#xD;
             administration of drugs on the exclusion list&#xD;
&#xD;
          -  Previous exposure to the CETP inhibitors dalcetrapib or evacetrapib within the last 3&#xD;
             months or anacetrapib within the last 12 months&#xD;
&#xD;
          -  Any planned coronary angiography or coronary revascularization procedure. If&#xD;
             angiography or revascularization is planned, participants may be screened and enrolled&#xD;
             after all such planned procedures are completed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cottonwood</city>
        <state>Arizona</state>
        <zip>86326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fleming Island</city>
        <state>Florida</state>
        <zip>32003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jacksonville Beach</city>
        <state>Florida</state>
        <zip>FL</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33777</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Margate</city>
        <state>Florida</state>
        <zip>33063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ponte Vedra</city>
        <state>Florida</state>
        <zip>32081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Safety Harbor</city>
        <state>Florida</state>
        <zip>34695</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Covington</city>
        <state>Georgia</state>
        <zip>30014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cumming</city>
        <state>Georgia</state>
        <zip>30041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tucker</city>
        <state>Georgia</state>
        <zip>30084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bannockburn</city>
        <state>Illinois</state>
        <zip>60015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jerseyville</city>
        <state>Illinois</state>
        <zip>62052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rock Island</city>
        <state>Illinois</state>
        <zip>61201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brownsburg</city>
        <state>Indiana</state>
        <zip>46112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hammond</city>
        <state>Indiana</state>
        <zip>46320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Waterloo</city>
        <state>Iowa</state>
        <zip>50702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hutchinson</city>
        <state>Kansas</state>
        <zip>67502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <zip>21804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Haverhill</city>
        <state>Massachusetts</state>
        <zip>01830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyannis</city>
        <state>Massachusetts</state>
        <zip>02601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Natick</city>
        <state>Massachusetts</state>
        <zip>01760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cadillac</city>
        <state>Michigan</state>
        <zip>49601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Marquette</city>
        <state>Michigan</state>
        <zip>49855</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Midland</city>
        <state>Michigan</state>
        <zip>48670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101 2595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Elizabeth</city>
        <state>New Jersey</state>
        <zip>07202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Elmer</city>
        <state>New Jersey</state>
        <zip>08318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Haddon Heights</city>
        <state>New Jersey</state>
        <zip>08035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mine Hill</city>
        <state>New Jersey</state>
        <zip>07803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sewell</city>
        <state>New Jersey</state>
        <zip>08080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Somerset</city>
        <state>New Jersey</state>
        <zip>08873</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kingston</city>
        <state>New York</state>
        <zip>12401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saratoga Springs</city>
        <state>New York</state>
        <zip>12866</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Southampton</city>
        <state>New York</state>
        <zip>11968</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Troy</city>
        <state>New York</state>
        <zip>12180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Westfield</city>
        <state>New York</state>
        <zip>14787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Elizabeth City</city>
        <state>North Carolina</state>
        <zip>27909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lenoir</city>
        <state>North Carolina</state>
        <zip>28645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mansfield</city>
        <state>Ohio</state>
        <zip>44906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sandusky</city>
        <state>Ohio</state>
        <zip>44870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Port Matilda</city>
        <state>Pennsylvania</state>
        <zip>16870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pottstown</city>
        <state>Pennsylvania</state>
        <zip>19464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Red Lion</city>
        <state>Pennsylvania</state>
        <zip>17356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cumberland</city>
        <state>Rhode Island</state>
        <zip>02864</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greeneville</city>
        <state>Tennessee</state>
        <zip>37745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37917</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tullahoma</city>
        <state>Tennessee</state>
        <zip>37388</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kerrville</city>
        <state>Texas</state>
        <zip>78028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kingwood</city>
        <state>Texas</state>
        <zip>77339</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <zip>24541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Harrisonburg</city>
        <state>Virginia</state>
        <zip>22801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oregon</city>
        <state>Wisconsin</state>
        <zip>53575</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Belgrano</city>
        <zip>C1428DCO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Buenos Aires</city>
        <zip>CBA 1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Coronel Suarez</city>
        <zip>B7540GHD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Córdoba</city>
        <zip>5006</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Luis</city>
        <zip>D5702JRS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Miguel De Tucuman</city>
        <zip>T4000NIL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2522</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Milton</city>
        <state>Queensland</state>
        <zip>4064</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Launceston</city>
        <state>Tasmania</state>
        <zip>7250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3162</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Windsor</city>
        <state>Victoria</state>
        <zip>3183</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Feldkirch</city>
        <zip>6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brussels</city>
        <zip>01200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Huy</city>
        <zip>4500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Merksem</city>
        <zip>2170</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tienen</city>
        <zip>3300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fortaleza</city>
        <zip>60430-370</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>22271-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gabrovo</city>
        <zip>5300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pazardzhik</city>
        <zip>4400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Smolyan</city>
        <zip>4700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 1V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mount Pearl</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1N 2C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 6V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5B 2P7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1J 2J9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 6K9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 2N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 7C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brossard</city>
        <state>Quebec</state>
        <zip>J4X 1S4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 5H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8Y6S9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Joilette</city>
        <state>Quebec</state>
        <zip>J6E 6J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Longueuil</city>
        <state>Quebec</state>
        <zip>J4M 2X1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint-Georges</city>
        <state>Quebec</state>
        <zip>G5Y 4T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St-Jerome</city>
        <state>Quebec</state>
        <zip>J7Z 5T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St-Lambert</city>
        <state>Quebec</state>
        <zip>J4P 2H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Changsha</city>
        <zip>410005</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guang Zhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Harbin</city>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shenyang</city>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cesky Krumlov</city>
        <zip>381 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hodonin</city>
        <zip>69501</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Marianske Lazne</city>
        <zip>35301</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pardubice</city>
        <zip>53002</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pisek</city>
        <zip>39701</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Prague</city>
        <zip>13000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pribram</city>
        <zip>26101</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Teplice</city>
        <zip>41501</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Copenhagen</city>
        <zip>2300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kobenhavn</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tallinn</city>
        <zip>10128</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Viljandi</city>
        <zip>71024</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Le Coudray</city>
        <zip>28630</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Altenburg</city>
        <zip>04600</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bielefeld</city>
        <zip>33604</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Frankfurt</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kassel</city>
        <zip>34121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tübingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warendorf</city>
        <zip>48231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Central</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bekescsaba</city>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Debrecen</city>
        <zip>4025</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hodmezovasarhely</city>
        <zip>6800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kalocsa</city>
        <zip>H-6300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Komarom</city>
        <zip>2921</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oroshaza</city>
        <zip>5901</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szekszard</city>
        <zip>7100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jerusalem</city>
        <zip>91004</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nazareth</city>
        <zip>16100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Safed</city>
        <zip>13110</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Castelfranco Veneto</city>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chieti Scalo</city>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Milano</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Daniele Del Friuli</city>
        <zip>33038</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sessa Aurunca</city>
        <zip>81037</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aichi</city>
        <zip>470-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chiba</city>
        <zip>270-2251</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ehime</city>
        <zip>798-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukuoka</city>
        <zip>830-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gunma</city>
        <zip>377-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyogo</city>
        <zip>665-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ibaraki</city>
        <zip>311-3193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ishikawa</city>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kanagawa</city>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kyoto</city>
        <zip>661-0042</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Okinawa</city>
        <zip>901-0493</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osaka</city>
        <zip>581-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saitama</city>
        <zip>351-0102</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shizuoka</city>
        <zip>411-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8539</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>152-8902</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yamaguchi</city>
        <zip>740-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Anyang</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chungbuk</city>
        <zip>361-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Daejeon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gangwon-Do</city>
        <zip>200-722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Goyang</city>
        <zip>410-773</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gwangju</city>
        <zip>510-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-10323</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chihuahua</city>
        <zip>31238</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cul Sinaloa</city>
        <zip>80020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guadalajara</city>
        <zip>44130</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Huixquilucan</city>
        <zip>52763</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mexico City</city>
        <zip>11850</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Queretaro</city>
        <zip>76000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78216</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tampico</city>
        <zip>89000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tijuana</city>
        <zip>22500</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Amersfoort</city>
        <zip>3818 ES</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beverwijk</city>
        <zip>1942 LE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Delft</city>
        <zip>2625 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Den Helder</city>
        <zip>1782 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Deventer</city>
        <zip>7416 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Drachten</city>
        <zip>9202 NN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Heerlen</city>
        <zip>6401CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hilversum</city>
        <zip>1213 XZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hoogeveen</city>
        <zip>7909AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hoorn</city>
        <zip>1625 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>S-Hertogenbosch</city>
        <zip>5223 GV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tilburg</city>
        <zip>5042 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Waalwijk</city>
        <zip>5141 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zaandam</city>
        <zip>1502 DV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zwijndrecht</city>
        <zip>3331 LZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Addington</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Grafton</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamilton West</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Newtown</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tauranga</city>
        <zip>3140</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Westlake</city>
        <zip>0620</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-863</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gdansk</city>
        <zip>80-126</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kutno</city>
        <zip>99-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lodz</city>
        <zip>94-255</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Olawa</city>
        <zip>55-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pulawy</city>
        <zip>24-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Skierniewice</city>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sobotka</city>
        <zip>55050</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-112</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ponce</city>
        <zip>00717-1322</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Trujillo Alto</city>
        <zip>00976</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Braila</city>
        <zip>810249</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Buzau</city>
        <zip>120203</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Focsani</city>
        <zip>620034</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oradea</city>
        <zip>410169</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Moscow</city>
        <zip>111020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196105</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tomsk</city>
        <zip>196105</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bardejov</city>
        <zip>08501</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bratislava</city>
        <zip>85101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kralovsky Chlmec</city>
        <zip>07701</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Presov</city>
        <zip>080 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zilina</city>
        <zip>010 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Alberton</city>
        <zip>1449</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bellville</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9300</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Goodwood</city>
        <zip>7460</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Johannesburg</city>
        <zip>1460</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kuilsriver</city>
        <zip>7580</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Newlands West</city>
        <zip>4035</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Parktown West</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Worcester</city>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>L´Hospitalet De Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Palma De Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lund</city>
        <zip>22221</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stockholm</city>
        <zip>11157</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Östersund</city>
        <zip>83183</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lugano</city>
        <zip>CH-6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zürich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kuei Shan Hsiang</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taichung City</city>
        <zip>40201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taipei</city>
        <zip>111</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ankara</city>
        <zip>06520</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Konya</city>
        <zip>42250</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kyiv</city>
        <zip>2091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lutsk</city>
        <zip>43024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Poltava</city>
        <zip>36038</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St. Stephen</city>
        <state>Cornwall</state>
        <zip>PL26 7RL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Welwyn Garden City</city>
        <state>Hertfordshire</state>
        <zip>AL7 4HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barnet</city>
        <state>Herts</state>
        <zip>EN5 3DJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stevenage</city>
        <state>Herts</state>
        <zip>SG4 7NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tooting</city>
        <state>London</state>
        <zip>SW17 ORE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wellingborough</city>
        <state>Northants</state>
        <zip>NN8 4RW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dudley</city>
        <state>West Midlands</state>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bath</city>
        <zip>BA2 4BY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Frome</city>
        <zip>BA11 1EZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>India</country>
    <country>Peru</country>
  </removed_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 12, 2012</study_first_submitted>
  <study_first_submitted_qc>September 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2012</study_first_posted>
  <results_first_submitted>February 18, 2018</results_first_submitted>
  <results_first_submitted_qc>April 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 16, 2018</results_first_posted>
  <disposition_first_submitted>August 13, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>August 13, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 16, 2016</disposition_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evacetrapib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Non-Completers: Participants &quot;Known to be Alive at Study End&quot; is a subset of those who did not withdraw consent and later found to be alive from public sources. &quot;Lost to follow-up&quot; is a subset of those who did not withdraw consent for whom study end vital status could not be ascertained.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Evacetrapib</title>
          <description>Evacetrapib 130 milligram (mg) tablet, administered orally once daily for up to 4 years. Participants will also receive standard of care for high-risk vascular disease (HRVD).</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo, tablet administered orally once daily for up to 4 years. Participants will also receive standard of care for HRVD.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6038"/>
                <participants group_id="P2" count="6054"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="6036"/>
                <participants group_id="P2" count="6052"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5926"/>
                <participants group_id="P2" count="5934"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Known to be Alive at Study End</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Evacetrapib</title>
          <description>Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6038"/>
            <count group_id="B2" value="6054"/>
            <count group_id="B3" value="12092"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.791" spread="9.3849"/>
                    <measurement group_id="B2" value="64.994" spread="9.4591"/>
                    <measurement group_id="B3" value="64.892" spread="9.4223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1390"/>
                    <measurement group_id="B2" value="1394"/>
                    <measurement group_id="B3" value="2784"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4648"/>
                    <measurement group_id="B2" value="4660"/>
                    <measurement group_id="B3" value="9308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="500"/>
                    <measurement group_id="B2" value="522"/>
                    <measurement group_id="B3" value="1022"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5394"/>
                    <measurement group_id="B2" value="5386"/>
                    <measurement group_id="B3" value="10780"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="243"/>
                    <measurement group_id="B2" value="226"/>
                    <measurement group_id="B3" value="469"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="650"/>
                    <measurement group_id="B2" value="640"/>
                    <measurement group_id="B3" value="1290"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="294"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4933"/>
                    <measurement group_id="B2" value="4971"/>
                    <measurement group_id="B3" value="9904"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2235"/>
                    <measurement group_id="B2" value="2240"/>
                    <measurement group_id="B3" value="4475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="221"/>
                    <measurement group_id="B3" value="445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="243"/>
                    <measurement group_id="B2" value="240"/>
                    <measurement group_id="B3" value="483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lithuania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="626"/>
                    <measurement group_id="B2" value="619"/>
                    <measurement group_id="B3" value="1245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="235"/>
                    <measurement group_id="B2" value="231"/>
                    <measurement group_id="B3" value="466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Composite Primary Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, Coronary Revascularization, or Hospitalization for Unstable Angina (UA)</title>
        <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
        <time_frame>Baseline to Study Completion (Up to 4 years)</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Evacetrapib</title>
            <description>Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite Primary Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, Coronary Revascularization, or Hospitalization for Unstable Angina (UA)</title>
          <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
          <population>All randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6038"/>
                <count group_id="O2" value="6054"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="779"/>
                    <measurement group_id="O2" value="776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary Endpoint: Time to First Occurrence of the Composite Primary Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, Coronary Revascularization, or Hospitalization for Unstable Angina (UA)</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.9054</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.006</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.911</ci_lower_limit>
            <ci_upper_limit>1.111</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline to 3 Months in Low-Density (LDL-C) and High-Density Lipoprotein Cholesterol (HDL-C) Levels</title>
        <time_frame>Baseline, 3 Months</time_frame>
        <population>All randomized participants with evaluable LDL-C and HDL-C levels.</population>
        <group_list>
          <group group_id="O1">
            <title>Evacetrapib</title>
            <description>Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline to 3 Months in Low-Density (LDL-C) and High-Density Lipoprotein Cholesterol (HDL-C) Levels</title>
          <population>All randomized participants with evaluable LDL-C and HDL-C levels.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6038"/>
                <count group_id="O2" value="6054"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5760"/>
                    <count group_id="O2" value="5786"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.12" spread="27.583"/>
                    <measurement group_id="O2" value="5.99" spread="29.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5760"/>
                    <count group_id="O2" value="5788"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.18" spread="57.204"/>
                    <measurement group_id="O2" value="1.63" spread="17.455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LDL-C</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-37.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.15</ci_lower_limit>
            <ci_upper_limit>-36.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HDL-C</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>131.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>130.01</ci_lower_limit>
            <ci_upper_limit>133.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite Endpoint of All-Cause Mortality, MI, Stroke, Coronary Revascularization, or Hospitalization for UA</title>
        <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
        <time_frame>Baseline through End of Study (Up to 4 years)</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Evacetrapib</title>
            <description>Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite Endpoint of All-Cause Mortality, MI, Stroke, Coronary Revascularization, or Hospitalization for UA</title>
          <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
          <population>All randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6038"/>
                <count group_id="O2" value="6054"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="857"/>
                    <measurement group_id="O2" value="867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time to First Occurrence of the Composite Endpoint of All-Cause Mortality, MI, Stroke, Coronary Revascularization, or Hospitalization for UA</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.8463</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.991</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.901</ci_lower_limit>
            <ci_upper_limit>1.089</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite Endpoint of CV Death, MI, or Coronary Revascularization</title>
        <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
        <time_frame>Baseline through End of Study (Up to 4 years)</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Evacetrapib</title>
            <description>Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite Endpoint of CV Death, MI, or Coronary Revascularization</title>
          <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
          <population>All randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6038"/>
                <count group_id="O2" value="6054"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="690"/>
                    <measurement group_id="O2" value="691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time to First Occurrence of the Composite Endpoint of CV Death, MI, or Coronary Revascularization</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.9874</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.001</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.901</ci_lower_limit>
            <ci_upper_limit>1.112</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite Endpoint of CV Death, MI, Stroke, or Hospitalization for UA</title>
        <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
        <time_frame>Baseline through End of Study (Up to 4 years)</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Evacetrapib</title>
            <description>Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite Endpoint of CV Death, MI, Stroke, or Hospitalization for UA</title>
          <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
          <population>All randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6038"/>
                <count group_id="O2" value="6054"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="571"/>
                    <measurement group_id="O2" value="570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time to First Occurrence of the Composite Endpoint of CV Death, MI, Stroke, or Hospitalization for UA</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.9574</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.003</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.893</ci_lower_limit>
            <ci_upper_limit>1.127</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Triple Composite Endpoint of CV Death, MI, or Stroke</title>
        <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
        <time_frame>Baseline through End of Study (Up to 4 years)</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Evacetrapib</title>
            <description>Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Triple Composite Endpoint of CV Death, MI, or Stroke</title>
          <description>For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.</description>
          <population>All randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6038"/>
                <count group_id="O2" value="6054"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="437"/>
                    <measurement group_id="O2" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time to First Occurrence of Triple Composite Endpoint of CV Death, MI, or Stroke</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.5917</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.965</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.846</ci_lower_limit>
            <ci_upper_limit>1.100</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.</desc>
      <group_list>
        <group group_id="E1">
          <title>Evacetrapib</title>
          <description>Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2306" subjects_at_risk="6036"/>
                <counts group_id="E2" subjects_affected="2341" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="30" subjects_at_risk="6036"/>
                <counts group_id="E2" events="46" subjects_affected="38" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aplastic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Heparin-induced thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy mediastinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pernicious anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spontaneous haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="168" subjects_affected="146" subjects_at_risk="6036"/>
                <counts group_id="E2" events="149" subjects_affected="137" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adams-stokes syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="113" subjects_affected="102" subjects_at_risk="6036"/>
                <counts group_id="E2" events="103" subjects_affected="98" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="389" subjects_affected="298" subjects_at_risk="6036"/>
                <counts group_id="E2" events="363" subjects_affected="289" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic valve sclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="109" subjects_affected="86" subjects_at_risk="6036"/>
                <counts group_id="E2" events="94" subjects_affected="78" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="6036"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="6036"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="79" subjects_affected="67" subjects_at_risk="6036"/>
                <counts group_id="E2" events="78" subjects_affected="63" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="134" subjects_affected="95" subjects_at_risk="6036"/>
                <counts group_id="E2" events="138" subjects_affected="103" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiorenal syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chronotropic incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="40" subjects_affected="37" subjects_at_risk="6036"/>
                <counts group_id="E2" events="45" subjects_affected="44" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dressler's syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Microvascular coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="88" subjects_affected="82" subjects_at_risk="6036"/>
                <counts group_id="E2" events="107" subjects_affected="100" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myocardial rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nodal rhythm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Postinfarction angina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Systolic dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ventricle rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ventricular hypokinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="6036"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wolff-parkinson-white syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous malformation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Leukodystrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4658"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Conductive deafness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Eustachian tube dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Otosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Age-related macular degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="6036"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cataract nuclear</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ectropion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Entropion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Idiopathic orbital inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Keratopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lens dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Open angle glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Optic atrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Optic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal compartment syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="6036"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal wall cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Alcoholic pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coeliac artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colitis microscopic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colonic fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dieulafoy's vascular malformation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Duodenal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastric cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="6036"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastritis alcoholic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="6036"/>
                <counts group_id="E2" events="32" subjects_affected="26" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Glossitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Heyde's syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="6036"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intestinal prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Jejunal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Large intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Large intestinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Localised intraabdominal fluid collection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mallory-weiss syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mesenteric vascular insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oedematous pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophageal achalasia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophageal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatic pseudocyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatitis haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peritoneal adhesions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumoperitoneum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rectal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Retroperitoneal effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Salivary gland mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tongue haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tongue oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="38" subjects_affected="37" subjects_at_risk="6036"/>
                <counts group_id="E2" events="42" subjects_affected="34" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="6036"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Device end of service</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Device inappropriate shock delivery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Device material issue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Exercise tolerance decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Implant site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Incarcerated hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ischaemic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lead dislodgement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Necrobiosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="123" subjects_affected="107" subjects_at_risk="6036"/>
                <counts group_id="E2" events="118" subjects_affected="108" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pelvic mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Precancerous mucosal lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Stent-graft endoleak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="6036"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular stent occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular stent restenosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular stent stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular stent thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Biliary tract disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="6036"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="6036"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="6036"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatic lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hydrocholecystis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ischaemic hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Jaundice extrahepatic obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abdominal wall infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abscess of salivary gland</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arteriosclerotic gangrene</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arteritis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Breast cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="6036"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="48" subjects_affected="41" subjects_at_risk="6036"/>
                <counts group_id="E2" events="45" subjects_affected="42" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholangitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Clostridium difficile sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colonic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Endocarditis enterococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Enterobacter infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Enterococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4648"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Escherichia pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gallbladder abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gallbladder empyema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="6036"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Graft infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>H1n1 influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatitis c</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Implant site cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Implant site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Infected bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Infected fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Infected seroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Infusion site cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Infusion site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Keratitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nail bed infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Orbital infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Osteomyelitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Parvovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Penile abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4648"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Perihepatic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="128" subjects_affected="115" subjects_at_risk="6036"/>
                <counts group_id="E2" events="122" subjects_affected="112" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia chlamydial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia parainfluenzae viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post procedural cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="49" subjects_affected="44" subjects_at_risk="6036"/>
                <counts group_id="E2" events="32" subjects_affected="28" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sinusitis fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal cord abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Staphylococcal mediastinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="6036"/>
                <counts group_id="E2" events="36" subjects_affected="32" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="6036"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Viral labyrinthitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wound infection bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Accidental exposure to product</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anal injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anastomotic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anastomotic ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chemical burn of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chemical injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colon injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Contrast media reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Crush injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cystitis radiation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="40" subjects_affected="39" subjects_at_risk="6036"/>
                <counts group_id="E2" events="53" subjects_affected="50" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal anastomotic complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Heat illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Muscle contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nerve root injury lumbar</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral arterial reocclusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral artery restenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post concussion syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post laminectomy syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post procedural myocardial infarction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post procedural stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Postoperative fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Postoperative respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Postoperative thoracic procedure complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="6036"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal cord injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal cord injury cervical</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Stoma site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Traumatic amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Traumatic liver injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular graft thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm ruptured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Angiogram</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anticoagulation drug level above therapeutic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arteriogram</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="6036"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arteriogram renal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Biopsy brain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Blood osmolarity decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac function test</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac stress test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiovascular evaluation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiovascular examination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carotid bruit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Catheterisation cardiac</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="6036"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Clostridium test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colonoscopy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Computerised tomogram</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Computerised tomogram thorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diagnostic procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Electrocardiogram qt prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Endoscopy gastrointestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>International normalised ratio decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Investigation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myocardial necrosis marker increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophagogastroduodenoscopy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral arteriogram</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4648"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ureteroscopy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vitamin b12 decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="6036"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6036"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hyperosmolar hyperglycaemic state</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="6036"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vitamin b12 deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankylosing spondylitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="6036"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Facet joint syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Joint instability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Kyphosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ligament laxity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="6036"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="6036"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Neuropathic arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="76" subjects_affected="70" subjects_at_risk="6036"/>
                <counts group_id="E2" events="75" subjects_affected="66" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vertebral foraminal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adenosquamous cell lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anaplastic astrocytoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma stage iv</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="6036"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Basosquamous carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Benign gastric neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of adrenal gland</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of spinal cord</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Benign renal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Borderline mucinous tumour of ovary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bronchial neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Burkitt's lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Buschke-lowenstein's tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the gastrointestinal tract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1388"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia stage 0</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colon cancer stage 0</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colon cancer stage iii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colon cancer stage iv</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colorectal cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colorectal cancer stage iv</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Desmoplastic melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diffuse large b-cell lymphoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diffuse large b-cell lymphoma recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diffuse large b-cell lymphoma stage ii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diffuse large b-cell lymphoma stage iii</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ewing's sarcoma metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Fallopian tube cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
              <event>
                <sub_title>Fibrous histiocytoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gallbladder adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastric adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gingival cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemangioma of liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease stage iv</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intestinal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Invasive breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Invasive lobular breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Keratinising squamous cell carcinoma of nasopharynx</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Large intestine benign neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Laryngeal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lip squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage i</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage ii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage iii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage ii</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage iii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage iv</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="6036"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage i</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage iii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lymphocytic lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Malignant fibrous histiocytoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of unknown primary site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mediastinum neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Meningioma malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Metastases to salivary gland</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myxofibrosarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nasal sinus cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nasopharyngeal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Neoplasm prostate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma metastatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Non-hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage iii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage iiia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage iv</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma stage 0</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oral cavity cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oropharyngeal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Oropharyngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatic neuroendocrine tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Papillary cystadenoma lymphomatosum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Phaeochromocytoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pituitary tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Polycythaemia vera</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="4648"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4648"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage ii</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4648"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage iv</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4648"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rectal cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rectal cancer stage 0</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sinonasal papilloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal cord neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the oral cavity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the tongue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the vulva</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>T-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Testicular neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4648"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Testicular seminoma (pure)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Throat cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thymoma malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tongue carcinoma stage iv</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tonsil cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ureteric cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1388"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Uterine neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute disseminated encephalomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Brain mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Brain stem stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="6036"/>
                <counts group_id="E2" events="42" subjects_affected="39" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carotid sinus syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cerebellar ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cerebellar syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cerebral artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="63" subjects_affected="61" subjects_at_risk="6036"/>
                <counts group_id="E2" events="65" subjects_affected="62" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Complex regional pain syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dementia alzheimer's type</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Embolic cerebral infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Essential tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Guillain-barre syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemorrhagic transformation stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="6036"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lumbosacral radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Moyamoya disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myelitis transverse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nerve root compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Postictal paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Quadriparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Quadriplegia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Radicular syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="8" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal claudication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal cord infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal cord oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="48" subjects_affected="46" subjects_at_risk="6036"/>
                <counts group_id="E2" events="54" subjects_affected="52" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thalamus haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Toxic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="44" subjects_affected="37" subjects_at_risk="6036"/>
                <counts group_id="E2" events="42" subjects_affected="39" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Uraemic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vasogenic cerebral oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vertebral artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vertigo cns origin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Viith nerve paralysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vith nerve paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vith nerve paresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Acute stress disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with depressed mood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with mixed disturbance of emotion and conduct</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Delirium tremens</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Generalised anxiety disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypomania</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Psychogenic seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="58" subjects_affected="48" subjects_at_risk="6036"/>
                <counts group_id="E2" events="81" subjects_affected="67" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bladder outlet obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cystitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Glomerulosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypotonic urinary bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="6036"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nephrosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pelvi-ureteric obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Prerenal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ureteral disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urethral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Amastia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="4648"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1388"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1388"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
              <event>
                <sub_title>Penile necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Peyronie's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4648"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="4648"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
              <event>
                <sub_title>Testicular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4648"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1388"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1388"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="6036"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Alveolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="55" subjects_affected="43" subjects_at_risk="6036"/>
                <counts group_id="E2" events="55" subjects_affected="47" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Chylothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="6036"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung consolidation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mediastinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pickwickian syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="6036"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6036"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="6036"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tracheomalacia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dermatomyositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Henoch-schonlein purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypersensitivity vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vasculitic rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Adrenalectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Analgesic therapy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aneurysm repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Angioplasty</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="6036"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ankle arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm repair</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic bypass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic valve repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic valve replacement</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arterial stent insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atherectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Atrial septal defect repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Autonomic nerve operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bladder neck suspension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1388"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bone operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Bronchial lesion excision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cancer surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac ablation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker battery replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac rehabilitation therapy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardiac resynchronisation therapy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cardioversion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carotid angioplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carotid endarterectomy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carotid revascularisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Carpal tunnel decompression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Catheter placement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colectomy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Colostomy closure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="6036"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" events="54" subjects_affected="54" subjects_at_risk="6036"/>
                <counts group_id="E2" events="59" subjects_affected="59" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Coronary revascularisation</sub_title>
                <counts group_id="E1" events="92" subjects_affected="82" subjects_at_risk="6036"/>
                <counts group_id="E2" events="89" subjects_affected="79" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Cox-maze procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Debridement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Diaphragmatic operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Elective surgery</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Endarterectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Endovenous ablation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Explorative laparotomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Exploratory operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Eye operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Foot amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastric bypass</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Gastrointestinal endoscopic therapy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haematoma evacuation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Heart valve replacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hernia repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>High frequency ablation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hip surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1388"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1394"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator insertion</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Incisional drainage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Incisional hernia repair</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intervertebral disc operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intraocular lens implant</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Joint arthroplasty</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="6036"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Knee operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Leg amputation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lens extraction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lipoma excision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Medical device change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Medical device removal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Mitral valve replacement</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nephrectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Open reduction of fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Osteosynthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Osteotomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreatectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pancreaticoduodenectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Penile repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Percutaneous coronary intervention</sub_title>
                <counts group_id="E1" events="217" subjects_affected="192" subjects_at_risk="6036"/>
                <counts group_id="E2" events="214" subjects_affected="182" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral artery angioplasty</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral artery bypass</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral artery stent insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral endarterectomy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral nerve transposition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral revascularisation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Prostate ablation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Prostatectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Radioactive iodine therapy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rectal prolapse repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal artery angioplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Renal sympathetic nerve ablation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Resection of rectum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Resuscitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Retinopexy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Rotator cuff repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Shoulder arthroplasty</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Shoulder operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Skin neoplasm excision</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal decompression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal fusion surgery</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal laminectomy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Spinal operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Stent placement</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Sympathectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tenotomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Therapeutic embolisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Therapy cessation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thrombectomy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thrombosis prophylaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thyroidectomy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Toe amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tongue operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Total adrenalectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Transmyocardial revascularisation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Transurethral bladder resection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Transurethral prostatectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4648"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4658"/>
              </event>
              <event>
                <sub_title>Tricuspid valve repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Tumour excision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ureteral stent insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ureteral stent removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1388"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Valvuloplasty cardiac</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular graft</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Venous stent insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Ventricular assist device insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vitrectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Wound drainage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="6036"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic elongation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="6036"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Aortitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arterial disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arterial insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arterial perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Artery dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Axillary vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Blood pressure inadequately controlled</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Brachiocephalic artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Embolism arterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Femoral artery aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Femoral artery perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="6036"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6036"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Iliac artery rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6036"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lymphatic fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Lymphorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="66" subjects_affected="52" subjects_at_risk="6036"/>
                <counts group_id="E2" events="66" subjects_affected="50" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="6036"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="6036"/>
                <counts group_id="E2" events="25" subjects_affected="20" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="6036"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Subclavian artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Subclavian artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vascular occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2659" subjects_at_risk="6036"/>
                <counts group_id="E2" subjects_affected="2529" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="568" subjects_affected="472" subjects_at_risk="6036"/>
                <counts group_id="E2" events="484" subjects_affected="414" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="456" subjects_affected="363" subjects_at_risk="6036"/>
                <counts group_id="E2" events="443" subjects_affected="375" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="603" subjects_affected="452" subjects_at_risk="6036"/>
                <counts group_id="E2" events="602" subjects_affected="465" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="397" subjects_affected="327" subjects_at_risk="6036"/>
                <counts group_id="E2" events="410" subjects_affected="327" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="426" subjects_affected="375" subjects_at_risk="6036"/>
                <counts group_id="E2" events="425" subjects_affected="370" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="442" subjects_affected="399" subjects_at_risk="6036"/>
                <counts group_id="E2" events="412" subjects_affected="379" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="412" subjects_affected="339" subjects_at_risk="6036"/>
                <counts group_id="E2" events="388" subjects_affected="329" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="435" subjects_affected="389" subjects_at_risk="6036"/>
                <counts group_id="E2" events="407" subjects_affected="352" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="367" subjects_affected="327" subjects_at_risk="6036"/>
                <counts group_id="E2" events="304" subjects_affected="279" subjects_at_risk="6052"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="339" subjects_affected="305" subjects_at_risk="6036"/>
                <counts group_id="E2" events="341" subjects_affected="307" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="508" subjects_affected="453" subjects_at_risk="6036"/>
                <counts group_id="E2" events="466" subjects_affected="403" subjects_at_risk="6052"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01687998
org study id: 11949
secondary id: I1V-MC-EIAN
nct id: NCT01687998
lead sponsor: 
collaborator: 
has dmc: Yes
The purpose of the ACCELERATE study is to evaluate the efficacy and safety of evacetrapib in
      participants with high-risk vascular disease (HRVD).
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Number of Participants With Composite Primary Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, Coronary Revascularization, or Hospitalization for Unstable Angina (UA)
time frame: Baseline to Study Completion (Up to 4 years)
description: For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.
measure: Mean Percent Change From Baseline to 3 Months in Low-Density (LDL-C) and High-Density Lipoprotein Cholesterol (HDL-C) Levels
time frame: Baseline, 3 Months
measure: Number of Participants With Composite Endpoint of All-Cause Mortality, MI, Stroke, Coronary Revascularization, or Hospitalization for UA
time frame: Baseline through End of Study (Up to 4 years)
description: For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.
measure: Number of Participants With Composite Endpoint of CV Death, MI, or Coronary Revascularization
time frame: Baseline through End of Study (Up to 4 years)
description: For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.
measure: Number of Participants With Composite Endpoint of CV Death, MI, Stroke, or Hospitalization for UA
time frame: Baseline through End of Study (Up to 4 years)
description: For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.
measure: Number of Participants With Triple Composite Endpoint of CV Death, MI, or Stroke
time frame: Baseline through End of Study (Up to 4 years)
description: For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.
arm group label: Evacetrapib
arm group type: Experimental
description: Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants will also receive standard of care for high-risk vascular disease (HRVD).
arm group label: Placebo
arm group type: Placebo Comparator
description: Placebo, tablet administered orally once daily for up to 4 years. Participants will also receive standard of care for HRVD.
intervention type: Drug
intervention name: Evacetrapib
description: Administered Orally
arm group label: Evacetrapib
other name: LY2484595
intervention type: Drug
intervention name: Placebo
description: Administered Orally
arm group label: Placebo
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: Study Director
affiliation: Eli Lilly and Company
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Argentina
country: Australia
country: Austria
country: Belgium
country: Brazil
country: Bulgaria
country: Canada
country: China
country: Czechia
country: Denmark
country: Estonia
country: France
country: Germany
country: Hong Kong
country: Hungary
country: Israel
country: Italy
country: Japan
country: Korea, Republic of
country: Lithuania
country: Mexico
country: Netherlands
country: New Zealand
country: Poland
country: Puerto Rico
country: Romania
country: Russian Federation
country: Slovakia
country: South Africa
country: Spain
country: Sweden
country: Switzerland
country: Taiwan
country: Turkey
country: Ukraine
country: United Kingdom
country: United States
country: Czech Republic
country: India
country: Peru
responsible party type: Sponsor
mesh term: Cardiovascular Diseases
mesh term: Evacetrapib
sharing ipd: Yes
ipd description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
ipd info type: Study Protocol
ipd info type: Statistical Analysis Plan (SAP)
ipd info type: Clinical Study Report (CSR)
ipd time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
ipd access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
ipd url: https://vivli.org/
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 